Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET
Aquestive Therapeutics (NASDAQ: AQST) has announced it will report its second quarter 2024 financial results and provide a business update after market close on August 6, 2024. The company, which focuses on developing innovative pharmaceutical delivery technologies, will host a conference call for investors at 8:00 a.m. ET on August 7, 2024. Interested parties can register in advance to obtain call-in details. A live webcast will be available on Aquestive's website, with a replay accessible for 30 days following the call in the Investors section of the company's website.
Aquestive Therapeutics (NASDAQ: AQST) ha annunciato che riporterà i suoi risultati finanziari del secondo trimestre 2024 e fornirà un aggiornamento aziendale dopo la chiusura del mercato il 6 agosto 2024. L'azienda, che si concentra sullo sviluppo di tecnologie innovative per la somministrazione farmacologica, ospiterà una conferenza telefonica per gli investitori alle 8:00 a.m. ET del 7 agosto 2024. Le parti interessate possono registrarsi in anticipo per ottenere i dettagli di accesso alla chiamata. Una diretta web sarà disponibile sul sito di Aquestive, con una replica accessibile per 30 giorni dopo la chiamata nella sezione Investitori del sito dell'azienda.
Aquestive Therapeutics (NASDAQ: AQST) ha anunciado que informará sobre sus resultados financieros del segundo trimestre de 2024 y proporcionará una actualización empresarial después del cierre del mercado el 6 de agosto de 2024. La compañía, que se centra en el desarrollo de tecnologías innovadoras de entrega farmacéutica, llevará a cabo una conferencia telefónica para inversores a las 8:00 a.m. ET del 7 de agosto de 2024. Las partes interesadas pueden registrarse con antelación para obtener detalles de acceso a la llamada. Una transmisión en vivo estará disponible en el sitio web de Aquestive, con una repetición accesible durante 30 días después de la llamada en la sección de Inversores del sitio web de la compañía.
Aquestive Therapeutics (NASDAQ: AQST)는 2024년 2분기 재무 결과를 발표하고 2024년 8월 6일 마감 후 사업 업데이트를 제공할 것이라고 발표했습니다. 혁신적인 의약품 전달 기술 개발에 중점을 두고 있는 이 회사는 2024년 8월 7일 오전 8시(ET)에 투자자들을 위한 컨퍼런스 콜을 주최할 예정입니다. 관심 있는 분들은 사전 등록을 통해 콜인 세부정보를 받을 수 있습니다. Aquestive의 웹사이트에서는 라이브 웹캐스트가 제공되며, 통화 이후 30일 동안 회사 웹사이트의 투자자 섹션에서 다시 볼 수 있습니다.
Aquestive Therapeutics (NASDAQ: AQST) a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 et fournira une mise à jour commerciale après la clôture des marchés le 6 août 2024. L'entreprise, qui se concentre sur le développement de technologies innovantes de livraison pharmaceutique, organisera une conférence téléphonique pour les investisseurs à 8h00 (ET) le 7 août 2024. Les parties intéressées peuvent s'inscrire à l'avance pour obtenir les détails de connexion. Un webinaire en direct sera disponible sur le site web d'Aquestive, avec un enregistrement accessible pendant 30 jours après la conférence dans la section Investisseurs du site de l'entreprise.
Aquestive Therapeutics (NASDAQ: AQST) hat bekannt gegeben, dass die Finanzergebnisse für das zweite Quartal 2024 nach Börsenschluss am 6. August 2024 veröffentlicht werden und ein Geschäftsupdate bereitgestellt wird. Das Unternehmen, das sich auf die Entwicklung innovativer Technologien zur Arzneimittelverabreichung konzentriert, wird am 7. August 2024 um 8:00 Uhr ET eine Telefonkonferenz für Investoren veranstalten. Interessierte können sich im Voraus registrieren, um die Zugangsdaten für den Anruf zu erhalten. Ein Live-Webcast wird auf der Webseite von Aquestive verfügbar sein, und eine Wiederholung wird 30 Tage nach dem Anruf im Bereich Investoren der Unternehmenswebsite zugänglich sein.
- None.
- None.
WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the second quarter ended June 30, 2024 and provide an update on recent developments in its business after market close on Tuesday, August 6, 2024.
Management will host a conference call for investors at 8:00 a.m. ET on Wednesday, August 7, 2024. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.
A live webcast of the call will be available on Aquestive’s website at: Second Quarter 2024 Earnings Call
Following the call, a replay of the webcast will be available on the Investors section of the Company’s website at https://investors.aquestive.com/events-and-presentations. The webcast will be archived for 30 days.
About Aquestive Therapeutics
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products marketed by its licensees in the U.S. and around the world, and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product pipeline focused on treating diseases of the central nervous system and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. For more information, visit Aquestive.com and follow us on LinkedIn.
Forward-Looking Statement
Certain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.
PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.
Investor Inquiries
ICR Westwicke
Stephanie Carrington
stephanie.carrington@westwicke.com
646-277-1282
FAQ
When will Aquestive Therapeutics (AQST) report its Q2 2024 financial results?
What time is Aquestive Therapeutics' (AQST) Q2 2024 earnings conference call?
How can investors access Aquestive Therapeutics' (AQST) Q2 2024 earnings call?
Where can investors find the replay of Aquestive Therapeutics' (AQST) Q2 2024 earnings call?
